GeneralConnection.com ➔ Dictionary
Dictionary Search

degrader

Synonyms

Noun

1. debaser

2. person, individual, someone, somebody, mortal, human, soul

Usage
Amphista Therapeutics receives FDA IND clearance for BRD9 degrader AMX-883 in acute myeloid leukaemia - Manufacturing Chemist
The FDA approved the first protein-degrader drug for breast cancer, and the twist is that it treats the target by making the body destroy it instead of blocking it - OkDiario
Roche bets $700M upfront on Nurix’s late-phase BTK degrader to tee up Lilly showdown - Fierce Biotech
Stifel reiterates Nurix stock rating on degrader therapy data By Investing.com - Investing.com Canada
Monte Rosa: Initiating Coverage With A Buy On Degrader Platform Potential - Seeking Alpha
J&J glows with $1B buyout of Firefly and its degrader platform tech - BioSpace
J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for $1B - BioPharma Dive
Activity of PROTAC MDM2 degrader in primary leukemia cells and PDX models - Nature
BeOne Medicines (ONC) Stock After New BRUKINSA And BTK Degrader Data What Is The Valuation Story Now - simplywall.st
Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy - Investing News Network
Nurix Therapeutics To Report Updated Phase 1A/B Results For Btk Degrader Bexobrutideg, Highlighting Durable Responses In Relapsed/Refractory Cll/Sll And Promising Activity In Earlier Lines Of Therapy - TradingView
First-in-Class Investigational Drug KRAS G12D Degrader Shows Promise in Lung and Pancreatic Cancers - Memorial Sloan Kettering Cancer Center
Amphista’s AMX-883 BRD9 degrader wins FDA IND clearance for AML - The Clinical Trial Vanguard
All-oral BeOne cancer combo hits 100% CLL response in trial - Stock Titan
J&J makes $1B bet on emerging DAC space by netting Firefly Bio - Fierce Biotech
A dihydrouracil CRBN ligand mitigates IMiD associated safety liabilities in heterobifunctional targeted protein degrader - Nature
Roche makes up to $2.3B blood cancer play with Nurix’s protein degrader - BioSpace
A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia - Nature
Gilead pays Kymera $45M to glue preclinical protein degrader onto burgeoning oncology pipeline - Fierce Biotech
A degrader of HER2 and EGFR abolishes p95HER2 and shows robust antitumor efficacy in HER2-positive breast cancer - Nature
Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca - PR Newswire
J&J inks $1B deal for Firefly Bio and its degrader-antibody platform - FirstWord Pharma
Development of a targeted BioPROTAC degrader selective for misfolded SOD1 - Nature
Blood–Brain Barrier (BBB)-Penetrable Androgen Receptor (AR) Degrader as a Potential Therapeutic Agent for Glioblastoma - ACS Publications
Discovery of a CNS active GSK3 degrader using orthogonally reactive linker screening - Nature
Discovery of a novel small molecule degrader of wild type and mutant estrogen receptors using DNA encoded libraries - Nature
A targeted protein degrader that doubles as a cancer vaccine - C&EN
AstraZeneca plucks preclinical EGFR degrader from Pinetree for $25M - Fierce Biotech
A rapid imaging-based screen for induced-proximity degraders identifies a potent degrader of oncoprotein SKP2 - Nature
Roche and C4 Therapeutics to advance degrader-antibody conjugates research - Pharmaceutical Technology
Nurix to work with Roche on BTK degrader in pact worth up to $2.3B - Endpoints News
Google, Johnson & Johnson back protein degrader start-up - C&EN
Roche, Nurix Team Up to Advance BTK Degrader Bexobrutideg - Yahoo Finance
A selective RPL15 PROTAC degrader enhances anti-PD-1 immunotherapy in a murine melanoma tumor model - Nature
Nurix signs 4th and largest partnership to develop BTK degrader - BioWorld News
Phase 1/2 trial launches of molecular glue degrader for ccRCC - Urology Times
Molecular Glue Degrader TRI-611 Receives FDA Fast Track for ALK+ NSCLC - Medical Professionals Reference
C4 ditches its EGFR degrader | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
Roche Strikes $2.3B Nurix Deal for BTK Degrader - Contract Pharma
Roche–Nurix $2.3 Billion Deal for BTK Degrader Bexobrutideg in Blood Cancers - Oncodaily
Roche and Nurix to advance potential best-in-class BTK degrader bexobrutideg - European Pharmaceutical Review
Degron Therapeutics Closes $40 Million Series A Extension to Support Molecular Glue Degrader Clinical Development - Business Wire
Fledgling French biotech pens $128M deal for Kezar's preclinical protein degrader program - Fierce Biotech
Amphista’s BRD9 degrader gains IND clearance for AML - BioWorld News
Degrader-antibody conjugates move past a rocky debut - BioCentury
Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference - PR Newswire
JNJ Acquires Firefly Bio: $1B Deal Targets KRAS Tumors with Degrader ADC Platform - News and Statistics - IndexBox
Discovery of a Potent and Selective TEAD Degrader with Durable Degradation Activity - Wiley
RBM39 degrader invigorates innate immunity to eradicate neuroblastoma despite cancer cell plasticity - Nature
Kymera Advances STAT6 Degrader KT-621 in Phase 2b Atopic Dermatitis, Asthma Trials - The Clinical Trial Vanguard
Orum pulls in $100M to fund degrader-antibody conjugate pipeline - FirstWord Pharma
Roche places a $1bn bet on C4T degrader-antibody conjugates - pharmaphorum
Discovery of KRAS(G12D) selective degrader ASP3082 - Nature
Roche And Nurix Therapeutics: Up To $2.3 Billion Collaboration For BTK Degrader Bexobrutideg - Pulse 2.0
Kymera Launches Parallel Phase 2b Trials for STAT6 Degrader KT-621 - The Clinical Trial Vanguard
Kymera's Oral STAT6 Degrader KT-621 Shows Biologic-Like Activity in Early Atopic Dermatitis Trial - Patient Care Online
Why Big Pharma Is Betting Billions on Protein Degraders for Cancer - PharmTech.com
2025 Michael Ferro – PCF Young Investigator Award - Prostate Cancer Foundation (PCF)
Read News and Stories about BTK degrader - Oncodaily
First Volunteer Dosed in Innocare’s New VAV1 Degrader Trial - The Clinical Trial Vanguard
New E3 ligase atlas aims to expand degrader drug discovery - BioWorld News
Harnessing artificial intelligence to identify Bufalin as a molecular glue degrader of estrogen receptor alpha - Nature
NRIX: BTK degrader advances in CLL with strong data, new trials, and broad pipeline momentum - TradingView
Roche Explores Degrader Antibody Conjugates To Support Oncology Pipeline - Yahoo Finance
AI builds dual-action cancer drug targeting PKMYT1 - Drug Target Review
When ADCs meet targeted protein degraders: The emerging field of degrader-antibody conjugates - Labiotech.eu
Pfizer-backed Triana scores $120M series B to take molecular glue degrader into clinic - Fierce Biotech
PAQ Therapeutics Announces Series B Extension, Bringing Total Series B Financing to $77 Million; First Patient Dosed in Phase 1 Trial of PT0511, a Pan-KRAS Degrader - PR Newswire
Degron Therapeutics Closes $40M Series A Extension Advancing Molecular Glue Degrader - Contract Pharma
EpiBiologics Advances Tissue Selective EGFR Degrader EPI 326 Into First In Human Clinical Study - BioPharma APAC
Neomorph secures $100M Series B to scale molecular glue degrader pipeline - The Pharma Letter
Arvinas and Pfizer seek a new home for protein degrader drug - Chemistry World
Nurix trims workforce as pivotal trial for lead BTK degrader kicks off - Fierce Biotech
Developing a CITK protein degrader using the QuicTPD™ platform - Chemistry World
Roche To Collaborate With Nurix Therapeutics On BTK Degrader Bexobrutideg - TradingView
Transcriptomic and epigenetic profiling of neuroblastoma states in response to RBM39 degrader - Nature
Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology - GlobeNewswire
ESMO 2025: Phase 1 Study of QLH12016, an Androgen Receptor PROTAC Degrader in Heavily Pretreated Patients with mCRPC: Safety, Tolerability, and Antitumor Activity - UroToday
New SMARCA2 degrader for SMARCA4-deficient cancers described - BioWorld News
Kymera’s IRF5 degrader shows potential in IBD treatment - BioWorld News
Roche, C4 deepen alliance with bet on degrader-antibody hybrid modality - FirstWord Pharma
FTO degrader impairs ribosome biogenesis and protein translation in acute myeloid leukemia - Science | AAAS
Johnson & Johnson inks $1B deal for tech targeting 'undruggable' KRAS - Stock Titan
SEED Therapeutics Reports Tumor Eradication in a - GlobeNewswire
Accelerating protein degrader discovery with the direct-to-biology workflow - News-Medical
Orum Therapeutics Presents New Preclinical Data at AACR 2026 on ORM-1153, a CD123-Targeting Degrader-Antibody Conjugate, Highlighting Broad Activity in Acute Myeloid Leukemia and the Potential for Improved Efficacy and Tolerability - Business Wire
Sanofi-led trial of new oral inflammation drug ties to $975M - Stock Titan
Mode of action of a DCAF16-recruiting targeted glue that can selectively degrade BRD9 - Nature
Nurix jumps as investors digest newly announced global Roche partnership for BTK degrader bexobrutideg - Quiver Quantitative
Protein degraders gain speed as Arvinas scores landmark approval - Pharma Voice
Former Genentech leaders’ protein degrader startup nets $107M - Endpoints News
Nurix: 'Strong Buy' Bexobruditeg Development And Dual Degrader Zelebrudomide (NASDAQ:NRIX) - Seeking Alpha
One to Watch: Kymera Therapeutics Oral STAT6 Degrader Fast-Tracked by U.S. FDA for AD - The Dermatology Digest
J&J makes $1B move for Firefly Bio, Carolyn Bertozzi’s twist on ADCs in KRAS field - Endpoints News
KT-621 Shows Strong Phase 1 Results as First-in-Class Oral STAT6 Degrader - Dermatology Times
Arvinas Joins Michael J. Fox Foundation LRRK2 Consortium to Advance Protein Degrader Research - geneonline.com
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026 - GlobeNewswire
Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting - GlobeNewswire
Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288 - GlobeNewswire
Novel PROTAC degrader targeting SAMHD1 disclosed - BioWorld News
Foreign Language Equivalents
Foreign Language Equivalents of 'degrader'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
edgrader,   dwgrader,   dergader,   derader,   degarder,   degraer,   degader,   degtader,   degrsder,   degrdaer,   degradeer,   drgrader,   ddegrader,   degraedr,   defrader,   degradrr,   degrafer,   degrrader,   degrador,   degradder,   degradwr,   dgerader,   segrader,   degraser,   fegrader,   dehrader,   degeader,   degrder,   egrader,   deggrader,   degraderr,   degrade,   deegrader,   dgrader,   degradre,   degraader,   degradet,   degradee,   degradr
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z